Drug Approval | April 06, 2024
Enhertu approved in the US as first tumour-agnostic HER2-directed therapy
Enhertu now has five approved indications with the latest in HER2-expressing (IHC 3+) metastatic cancers
Enhertu now has five approved indications with the latest in HER2-expressing (IHC 3+) metastatic cancers
Aurigene.AI is an end-to-end solution for small molecule drug discovery
First and only AKT inhibitor approved in Japan for breast cancer patients with specific biomarker alterations
The CRDMO site will add 120,000L manufacturing capacity to WuXi Biologics’ global network
Elegen is the only DNA manufacturer delivering the unique combination of complexity, length and NGS-verified accuracy within days
AbCellera will receive an upfront payment and is eligible to receive additional milestone payments
Acquisition of exclusive commercialization rights for European markets
The National One Health Mission will help India to achieve integrated disease control and pandemic preparedness
Cipla completes transfer of Generics Business Undertaking
The objective of GCMC is well aligned to WHO’s call to action and India’s National Biotechnology Development Strategy
Subscribe To Our Newsletter & Stay Updated
